C5 and cancer: Furthermore, human cerebral spinal fluid from CA patients shows an increase in C1q, C3, C3a, and C5 (44, 45), and people with defects in complement activation or who are taking the anti-C5 monoclonal antibody therapy, eculizumab, are at risk for invasive aspergillosis (46, 47).